INTRODUCTION
The diagnostic use of fine-needle aspiration (FNA) in the evaluation of salivary gland lesions has been well established by generating cost-effective care and appropriate management strategies, which may range from observation to radical surgery with neck dissection. [1] [2] [3] [4] [5] [6] Given the wide diversity of tumors arising in the salivary glands, there are many diagnostic challenges within salivary gland cytopathology, including the lack of a uniform reporting system. These challenges are amplified further by the fact that several low-grade carcinomas demonstrate significant morphologic overlap with their benign counterparts. In addition, the impression was that diagnoses in salivary gland cytology often are based on descriptive cytological interpretations, sometimes without conclusive evidence or a diagnostic category with which to guide management. This led a group of experienced cytopathologists and histopathologists to attempt to create a uniform cytological reporting scheme. The proposed system is based on key principles developed for standardized terminology systems adopted for other body sites (ie, uterine cervix, pancreas, thyroid, and urinary system). [5] [6] [7] [8] Emphasis will be placed on evidence-based literature regarding diagnostic categories and risk stratification. The standardization effort started in September 2015 at the European Congress of Cytology, which was held in Milan, Italy, under the umbrella of the American Society of Cytopathology (ASC) and the International Academy of Cytology (IAC). Subsequently, an international panel of 49 cytopathologists and histopathologists (the Milan group) was organized to establish a unified effort under the title of "The Milan System for Reporting Salivary Gland Cytopathology."
Before starting the task of constructing a taxonomy, the Milan group invited the international cytology and histology communities to answer a series of questions relevant to the framework of the developing system for reporting salivary cytology. Questions were generated in accord with the current literature and experience of the authors in the core group. Inquiries were directed toward the most significant and critical aspects of the daily practice of salivary gland cytopathology.
The purpose of this article is to analyze and share the information generated by the survey.
MATERIALS AND METHODS

Survey and Question Design
The Milan core group created 49 individual questions/ items that dealt with the proposed classification system, taxonomy, and interpretative criteria. The categories of questions reflected many of the proposed chapters for the Milan System atlas, including the nondiagnostic, benign, neoplastic, suspicious, and malignant categories as well as questions regarding the application of ancillary techniques. Many inquiries were intentionally open-ended and had to be answered via free text. It was planned to create a survey that would take 15 to 30 minutes to complete in 1 sitting. The survey was Web-based and developed using Qualtrics survey software (Qualtrics, Provo, Utah). Server space and access to the Qualtrics application was provided by the division of information technology at the University of Wisconsin in Madison. Invitations to participate were made through the Web sites of the ASC, IAC, and European Society of Pathology. The survey also was advertised through the ASC ListServe, and by informal contact with other national and international societies of pathology and cytopathology. Due to the length of the survey, the entire list of survey questions is not included in this article. However, they are available on request from the senior author (D.F.I.K.; dkurtycz@wisc.edu). Demographic information regarding type, volume, and years in practice was requested. Each user was asked for an e-mail address, but all responses were dissociated from this address to maintain anonymity.
Between November 27, 2015 and March 30, 2016, the survey was accessed 515 times by different participants; of these, only 133 provided their e-mail address. The survey was designed so that the survey participants were not required to respond to every question. The review and statistical analysis of the survey responses was undertaken by 2 of the authors (E.D.R. and D.F.I.K.). All statistical analysis was performed through tabular and summation features available in the Qualtrics software and by use of Excel spreadsheets (Microsoft Corporation, Redmond, Washington).
RESULTS
Demographics
There were 515 participants collected from an international audience. Extrapolating from the e-mail addresses, greater than one-third of the participants were from the United States; however, there were numerous respondents from Europe (Belgium, France, Germany, Greece, Italy, the Netherlands, Norway, Switzerland, and the United Kingdom). Participants from Australia, Canada, Japan, and Africa also were represented. The 4 initial questions dealt with participant practice type, experience, and certification. A total of 306 individuals provided information regarding their length of time in practice and claimed a collective cytologic experience of 5021 years. The range of experience in cytologic practice varied from 1 year to 43 years (mean, 16.4 years; standard deviation, 11.6 years), and included experience levels from recently graduated cytotechnologists to physicians who had been in practice Original Article for 50 years. A total of 350 individuals provided information regarding their level of certification (Fig. 1) . Approximately 52% of the respondents were pathologists, and 40% claimed specialty certification in cytopathology. Approximately 5% of respondents were pathologists with IAC certification and 22% of the participants were cytotechnologists (Fig. 1) . All respondents were cytopathology professionals (Fig. 1 ); 45% were certified by the American Board of Pathology with specialty certification in cytopathology, and an additional 6% were pathologists with at least anatomic pathology certification. One-third of the cytotechnologists had American Society for Clinical Pathology specialist certification (Specialist in Cytotechnology) ( Fig. 1) (Table 1) .
Collection of Responses
A majority of respondents (82%) agreed with the usefulness of ultrasound in obtaining a diagnostic FNA sample from a salivary gland lesion. Approximately 81% of the participants indicated that either they or their institution used radiologic guidance (ultrasound or computed tomography) to perform salivary gland FNA. Rapid on-site evaluation was reported to be performed by 59% of participants. Of 197 respondents, 175 (89%) reported using alcohol-based smears and 156 (79%) used air-dried smears, whereas 138 respondents (70%) reported using both air-dried and alcohol-fixed direct smear preparations. Use of Papanicolaou-stained liquid-based cytology was reported by 82 of 197 respondents (42%) and 49 of 197 respondents (25%) indicated the additional use of cell block preparations. Of the 197 respondents, 30 (15%) routinely used cytospin preparations (Thermo Scientific, Waltham, Massachusetts). Of 196 participants, 130 (66%) preferred using both alcohol-fixed and air-dried preparations. This combination was believed to be especially useful for the evaluation of matrix-containing salivary gland tumors. The idea of a tiered classification system for salivary gland FNA was favored by 72% of the participants (127 of 177 respondents), with the major categories being nondiagnostic, benign, neoplasms, suspicious for malignancy (SFM), and malignant.
A significant issue raised by the survey participants was that implementation of a tiered system may cause cytopathologists to check off boxes relating to defined diagnostic categories rather than providing a definitive surgical pathology type diagnosis. A minority of the 28% Survey on Salivary Gland Cytopathology/Rossi et al
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Sample Evaluation and Adequacy
The first query in this group was to define an acceptable upper limit for the percentage of "nondiagnostic/unsatisfactory" salivary gland FNAs; 178 respondents gave a range of 0% to 25%, with an average of 7.8% (standard deviation, 4.7%). Approximately one-half of the participants shared their opinion that 10% to 15% is the acceptable upper limit for the percentage of "nondiagnostic/unsatisfactory" cases. As a corollary, the survey inquired as to the minimum number of lesional and/or nonlesional cells that cytopathologists would require to consider a salivary gland aspirate as "benign" versus "nondiagnostic/unsatisfactory." A majority chose not to answer, indicating that such a number has not been established in the literature or that the respondents did not want to provide a fixed number. Some indicated that adequacy should be based on the clinical context and the experience of the cytopathologist. Contrasting opinions were offered regarding samples consisting of only benign salivary gland tissue. Approximately 48% of participants (89 of 184 participants) agreed that such samples should be diagnosed as "benign" whereas 34% said that they would call it "nondiagnostic/unsatisfactory," especially if there was clinical or radiologic evidence of a mass.
Cystic Lesions
Participants were asked about their approaches to acellular cyst contents with and without mucin. If mucin was detected in cyst contents, approximately 73% of participants (40 of 55 participants) indicated that they would add a comment raising the possibility of a mucoepidermoid (MEC) or squamous cell carcinoma association with mucinous cystic material, and they would generally refrain from calling cyst contents benign. Several participants emphasized the need for a morphologic description of cystic lesions, especially in cases lacking sufficient clinical history.
Nondiagnostic Category
When asked a general question regarding the nature of a "nondiagnostic/unsatisfactory" sample, the participants separated nondiagnostic samples into 2 subgroups: the first due to cyst contents only and the second due to poor quality of the specimen. The participants were asked about patient management in their institution in the face of an unsatisfactory or nondiagnostic sample and 67% of participants (122 of 181 participants) indicated that the management would be to repeat FNA, whereas 13% of participants (23 of 181 participants) indicated that patients would go directly to surgery. Some of the answers focused on the role of the clinical-radiological correlation as to the nature of the lesion and the need for a detailed morphologic description of the sample. Several respondents indicated that they prefer to ensure that what was observed on the slide was consistent with what the radiologist described. Without correlation, these participants would be more likely to call a sample "nondiagnostic."
Benign Category
The survey queried about the category of "benign" in the context of salivary gland cytology practice. This resulted in noteworthy responses that generated subsequent debate in the Milan core group. Many respondents stated that "benign cells" do not always constitute a benign diagnosis. Abnormal radiology demonstrating any mass lesion or clinical symptoms of nerve pain or paralysis would tend to generate an interpretation of nondiagnostic rather than benign for many participants. In addition, the majority of respondents suggested that there should be 2 diagnostic subgroups under the benign category, "nonneoplastic" and "neoplastic lesions," with different risks of malignancy and management options. When queried about their level of confidence in diagnosing several benign entities on cytomorphology, 94% of participants indicated they would diagnose acute or chronic sialadenitis, 86% would diagnose reactive salivary lymph node, 73% would diagnose lymphoepithelial sialadenitis, and 62% would diagnose mucocele. In the latter case, many were reasonably worried about MEC and indicated so in the commentary attached to the question. In addition, the participants included pleomorphic adenoma (PA) (86%), Warthin tumor (93%), oncocytoma (56%), schwannoma (68%), and lipoma (86%) in the category of benign neoplasms (Table 2) .
Atypical Category
The Milan group authors did not offer questions regarding respondent attitudes toward an atypical category first because of the desire to limit the number of survey questions and second because the concerns about the overuse of this diagnostic term (similar to what has been suggested by Original Article other classification schemes) is well known in all cytological systems.
Lesions of Uncertain Malignant Potential Category
The survey offered several text-based questions regarding different categories of lesions, with a special focus on lowgrade/low-risk neoplasms. Here, opinions exhibited significant variability, subjectivity, and a great deal of apprehension, mostly due to the difficulty in the interpretation of samples and regarding subsequent clinical and/or surgical management.
The survey clearly demonstrated the lack of a uniform point of view among the respondents. Several participants underscored the need for specific and detailed morphological features, which can be useful for a correct interpretation and diagnosis. Questions regarding the diagnosis and classification of the problematic group of "basaloid neoplasms" were included in this survey. The response was a broad range of answers that caused significant discussion among the Milan group as to how these lesions will be integrated into the reporting system. After further adjustments and refinements to the reporting system, it is clear that basaloid neoplasms will represent a distinct subgroup within the category of neoplastic lesions of uncertain malignant potential.
Suspicious for Malignancy Category
Approximately 78% of the participants (138 of 177 participants) indicated that they already use the SFM category in their practice. They subsequently were asked to provide a brief definition of SFM. The most frequent answers tended to be similar to those listed in the Bethesda Systems for the uterine cervix and thyroid: SFM should be used when there is atypia that is concerning for malignancy but the sample falls qualitatively or quantitatively short of a clear diagnosis of malignancy. A few participants stated they would use the SFM category any time there was any morphologic possibility of MEC, adenoid cystic carcinoma, or otherwise unclassifiable atypia. Again, a few respondents indicated that suspicious radiologic and clinical findings would influence their interpretation and might easily push them into making an interpretation of SFM. It is interesting to note that whereas 78% of the participants diagnose SGC cases as SFM, only 34% (51 of 150 participants) claimed to be aware of the risk of malignancy in their use of the term SFM, whereas 58% (87 of 150 participants) said they were not aware of the magnitude of risk. Many who claimed to know the risk of malignancy quoted a figure of approximately 80%. The majority of the participants made statements to the effect that SFM should be reserved for situations in which high-grade tumors were suspected. Approximately 5% of participants (8 of 156 participants) said that SFM was not relevant to their practice. A question regarding a possible subclassification into separate "suspicious for low-grade malignancy" and "suspicious for high-grade malignancy" categories was considered controversial because of a broad range of opinions. Respondents noted that difficulties in the discrimination between lowgrade and high-grade SFM categories are associated with scant material in some SFM cases and the difficulties in estimating the grade of nuclear features in others.
In addition, participants were asked if they render an SFM interpretation in salivary gland FNA samples when there are features of malignancy in a less-than-optimal specimen (eg, limited cellularity, poor preservation and fixation, or a lack of overt malignant features). A majority of respondents said yes (77%; 119 of 155 respondents), 16% said no (25 of 155 respondents), and 7% (11 of 155 respondents) said that the situation did not apply to their laboratory because they do not use the term "SFM." The survey asked about how a diagnosis of SFM is managed in their institution: 5% (8 of 169 respondents) indicated repeat FNA; 65% (110 of 169 respondents) proceed to surgical excision; 7% (12 of 169 respondents) go to core needle biopsy; and 23% (39 of 169 respondents) said "other," including the use of ancillary techniques (specifically immunocytochemistry in 25% [40 of 162 respondents], flow cytometry in 7% [11 of 162 respondents], and fluorescence in situ hybridization in 6% [9 of 162 respondents]) ( Table 3) .
Malignancy
When queried regarding what is needed for a diagnosis of malignancy, the majority of participants indicated that Survey on Salivary Gland Cytopathology/Rossi et al
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they rely on significant nuclear atypia. Others listed additional features such an evidence of necrosis, lack of artifact, cellularity, and unequivocal morphology for a definitive diagnosis of malignancy.
Respondents reiterated the well-known difficulties and issues in making the distinction between low-grade and high-grade malignancies, especially concerning samples including basaloid neoplasms and other entities. The responses demonstrated that cytopathologists had a range of opinions, and that different surgical approaches are used in their institutions. The survey asked about the management options for patients with a malignant diagnosis. The general response was surgical intervention, with low-grade tumors being locally excised with nerve-sparing procedures, whereas among patients with high-grade lesions, the nerve would be sacrificed and the procedure would be extended by a cervical lymph node dissection.
Use of Ancillary Tests
Several opinions emerged from this survey regarding the role of ancillary techniques in the field of malignant and indeterminate lesions. The majority of respondents (62%) claimed that they did not use ancillary techniques in salivary gland FNA cases diagnosed as malignant or that they performed different ancillary techniques (Table 4 ). The types of preparations used for ancillary technique analysis are shown in Table 3 . The reasons for the restricted adoption of ancillary techniques on FNA were attributed to the limited cytological material and the lack of diagnostic usefulness in classifying neoplasms. For those respondents who do use ancillary techniques, the majority reported using flow cytometry and 95% used immunohistochemistry, with p63 and CD117 being the common markers performed on cell block samples. These techniques are mostly adopted to rule out lymphomas, to subtype basaloid neoplasms, and to characterize high-grade carcinomas (Table 5) .
DISCUSSION
FNA has proven to be of significant value as an early step in the evaluation and diagnosis of salivary gland lesions. [1] [2] [3] [4] Although the majority of salivary gland lesions can be easily diagnosed on FNA, in some instances limited cellularity, morphologic variations, and the quality of some samples add to the diagnostic challenge and can lead to occasional missed diagnoses. Part of the canon of FNA is that improvements in the quality of the diagnosis are directly proportional to the quality of the sample. Several publications have documented a wide range of sensitivities and diagnostic accuracies for salivary gland FNA (87%-100%), which might be the result of heterogeneous sampling, morphologic similarity between some tumor types, and the experience of the observers. [7] [8] [9] [10] [11] [12] [13] [14] To come to terms with recognized diagnostic difficulties, some authors, such as Griffith et al and Wang et al, have proposed a risk stratification scheme, similar to what has been done for thyroid cytology, in which the risk of malignancy was provided for each diagnostic entity or category. 2, 4 This would provide clinicians with at least a probabilistic result on which to base therapy. Although these efforts may blossom in an institution or region, without widespread instruction or adoption by a professional society they are not going to be used or understood elsewhere. It has been noted in the cytologic literature of several organ systems that the lack of a uniform classification system impedes diagnostic efforts and thus impairs clinical management.
5-8
The history of The Milan System for Reporting Salivary Gland Cytopathology actually goes back to Boston during the United States and Canadian Academy of Pathology meeting held in March 2015, when a core group of similarly minded individuals met to 1) define a standardized international reporting system for salivary gland cytology based on clinical outcomes and evidencedbased analysis; 2) establish criteria for the detection and reporting of "neoplastic" salivary gland lesions by cytology; and 3) educate cytologists and clinicians regarding the usefulness, efficacy, and possible limitations of salivary gland cytology. The group expanded and brought their ideas to the 39th European Congress of Cytology held in Milan, Italy, in September 2015 and sought the involvement of professional societies. This group took their name from that meeting and subsequently was designated as the Milan System Task Force for Salivary Gland Cytopathology. While searching the literature and amassing scientific evidence, pathologists and cytopathologists from all over the world were invited to add their opinions and expertise. The Milan group developed a series of questions and put them into a Web-based survey, sponsored by the ASC, IAC, and the PSC. Participant answers were evaluated and used for the development of features and criteria for the Milan System.
The objective of the Milan System survey was to find out how the cytologic community would accept the idea of the tiered diagnostic system central to the heart of the Milan System, and to sift out opinion and attitudes regarding salivary gland FNA.
One of the early survey topics revolved around specimen adequacy and, not surprisingly, the responses were varied. When queried about the acceptable upper limit for "nondiagnostic/unsatisfactory" samples, the responses ranged from 0% to 25%, with an average of 7.8%, but nearly one-half of the survey respondents shared the opinion that an upper limit of 10% to 15% would be optimal. Many of the survey respondents could not offer a clear answer as to what sort of specimen constitutes an adequate sample. Some participants stated that such a number has not been established in the literature, whereas others pointed out the fact that such an evaluation has to be dictated by the clinical situation, including the radiologic evidence. Some participants did go so far as to offer numbers of cells and groups of cells similar to criteria seen in the thyroid literature. It is obvious from the responses that there is confusion and a need to establish a common guideline.
Another issue was the different approaches of participants to FNA samples that consist of only benign salivary gland material. Nearly one-half (48%) stated that they would classify the sample as "benign," but greater than one-third (34%) said it should be categorized as nondiagnostic due to the lack of lesional cells. Many indicated that the reasonable response to a sample of benign salivary gland elements should be defined by the framework of morphological, clinical, and radiologic findings and tempered by medical judgment in a multidisciplinary team. This is akin to the idea of the "triple test," in which an FNA diagnosis has to make sense in light of the morphologic, radiologic, and clinical features. If something is disparate, the interpretation must be reconsidered. It is obvious that in the face of a radiologically distinct mass, especially with invasive characteristics, a response of "benign salivary gland elements" is not going to answer the clinical question and an explanatory note will be needed. To correctly accomplish the evaluation, the cytologist will have to be aware of the patient's clinical and radiologic findings and, optimally, should discuss the matter with the clinician.
The survey participants indicated a preference for the division of benign diagnoses into nonneoplastic and neoplastic subgroups. The Milan group believed this was very reasonable and established categories and atlas chapters for benign nonneoplastic entities and benign neoplastic entities.
Although it was not specifically addressed in the survey, the Milan System will contain a category of atypia of undetermined significance, the details of which will be discussed and analyzed in the upcoming atlas. Atypia is always an area of controversy that is disliked by both clinicians and diagnosticians because it does not offer a clear clinical pathway forward, except to repeat FNA and to obtain more material. An interpretation of atypia reflects either: 1) quantitative or qualitative defects in the sample; 2) an inability of cytomorphology to resolve a diagnosis; or 3) a lack of experience and/or confidence in the interpretation. One of the aims of the Milan System is to decrease the percentage of atypical interpretations, provide a range of risk assessment, and hopefully restrict its use in clinical practice.
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October 2017 The survey obtained repeated responses highlighting concerns regarding diagnostic atypia and the potential for overlap of cytomorphologic features among different lesions that tend to impair the performance of salivary gland FNA and generate unacceptably high false-positive and false-negative rates. 1 This was highlighted by a recent publication by Tabatabai et al, in which the authors reviewed 5156 individual responses to 97 proficiency-type slide challenges from the College of American Pathologists Nongynecologic Cytology program by examining the accuracy and false-negative rate of adenoid cystic carcinoma (ACC). The study demonstrated that there are significant false-negative responses to ACC due to several common diagnostic pitfalls (ie, PA, monomorphic adenoma, lymphoma, and adenocarcinoma). 3 Overall, the majority of participants (72%) responded favorably to the idea of a tiered system for classifying salivary gland FNA, with different categories of nondiagnostic, benign, neoplasm, SFM, and malignant. Many of the remaining respondents (28%) were uncertain, and some objected to the general idea of classification guidelines that may reduce the cytological profession to screening tests and generic classifications. They do not want to witness cytology return to an era of checking off boxes on a form and would prefer to offer surgical pathology types of interpretative diagnoses. Conversely, it is interesting to note that surgical pathologists are being pressed to achieve uniformity through consensus-created synoptic reports and restricted diagnostic categories in electronic record systems.
Acceptance of the tiered concept will assist the Milan group in achieving a category scheme that allows for risk stratification and pathways for clinical management. The Milan group agreed that the risks associated with a given cytologic category should be modified by clinical and radiologic features. It is the aim of the Milan group to encourage large multicenter studies that will provide evidence to support or modify the categorization scheme. In salivary gland cytology, one of the major problems is the approach to lesions of low to intermediate malignant potential. The PSC presented a possible solution in their pancreaticobiliary guidelines, with the idea to group several tumors with uncertain malignant behaviors (ie, pancreatic neuroendocrine tumors, mucinous cystic neoplasms, solid pseudopapillary neoplasms, and other entities that only occasionally invade or metastasize) into a category called "neoplasm other" that is separate from "neoplasm benign" and "neoplasm malignant." It is deemed especially important that each entity in the "neoplasm other" category have a risk assessment based on the existing literature and be modified by future research. [5] [6] [7] [8] The salivary gland corollaries to the pancreatic lesions consist mostly of basaloid neoplasms, which not only have variable malignant potential but possess morphologic overlap that cause them to be among the most controversial and difficult areas of any salivary gland classification system. The survey reinforced a need for an SFM category in samples that suggest high-grade malignant tumors, but for some quantitative or qualitative reason an analyst cannot make the definitive diagnosis. SFM, previously proposed by Wang et al, 4 has been proposed for inclusion in the Milan System and questions regarding SFM were included in the survey. The answers revealed that the SFM category was both easily defined by the participants and regularly used by 78% of them. Greater than 75% of respondents indicated that the use of SFM was appropriate in cases of limited cellularity, poor preservation, or a deficit of sufficient malignant features. In answering some questions regarding SFM, respondents reiterated that they might be influenced by suspicious radiologic findings to alter their interpretation of atypical findings up to SFM. In most institutions, the response to a classification of SFM is surgical excision, with only a minority of cases going to repeat FNA or core needle biopsy. In the questions directed toward samples demonstrating overt malignancy, participants indicated that they would render a diagnosis of malignancy if the classic textbook-described features of malignancy are present. It is interesting to note that the majority of respondents expressed their preference to grade a malignant neoplasm based on the subsequent histology sample rather than on cytology. If grading could be achieved on cytology, it would be advantageous, even though both cases generally are managed by surgery; patients with low-grade tumors usually undergo nerve-sparing local excision whereas in patients with high-grade lesions nerves may not be spared and the surgery is extended to include cervical lymph node dissection.
The survey included questions regarding the use of ancillary techniques to obtain an overview of their perceived role in salivary gland FNA. The answers indicated that use of these techniques in the salivary gland was not very different from the use of ancillary methodology in the other body lesions sampled by FNA. The majority of the participants indicated that ancillary technologies are used from 0% to 10% of the time, mostly on cell block preparations. Those who did not tend to use ancillary methods, or used them infrequently, indicated that their use was proportional to clinical usefulness and its influence on management. Many also noted technical difficulties. Several respondents said that in many instances, there rarely was enough material on slides or in cell blocks with which to perform ancillary studies. Immunocytochemistry, flow cytometry, and fluorescence in situ hybridization were the most frequent tests used especially to rule out lymphoma, followed by the evaluation of high-grade carcinoma and basaloid neoplasms. Furthermore, the use of p63/calponin for myoepithelial cells, mucicarmine/D-PAS for MEC, and CD117/DOG-1 have been shown to have some usefulness in differentiating ACC from polymorphous adenocarcinoma and PA. Greater than 90% of the ancillary studies are performed on cell block material; however, > 25% of the participants indicated that ancillary studies also are performed directly on cytologic preparations.
Limitations to the Current Study
The design of the current study did not force each respondent to answer every question because the aim was to capture as many opinions and recommendations as possible to help the Milan core group generate a classification scheme that reflects the current environment and future of the practice of salivary gland cytopathology. However, the submitted answers and subsequent analysis led the Milan group to refine the tiered classification scheme and to generate 9 chapters, including 6 diagnostic categories: 1) nondiagnostic; 2) nonneoplastic; 3) atypia of undetermined significance; 4) neoplasms with 2 subcategories of a) neoplastic-benign and b) salivary lesions of uncertain malignant potential; 5) SFM; and 6) malignant. The remaining 3 chapters are dedicated to 1) a general overview of the Milan System and risk of malignancy; 2) the application of ancillary techniques, and 3) management. Each of the diagnostic chapters has information regarding specific risks of malignancy and clinical management strategies.
The results of the survey highlighted the usefulness of salivary gland FNA as an effective diagnostic procedure. However, the results underscored the worldwide diagnostic difficulties and heterogeneous approaches to salivary gland cytology. The results supported the need for a classification scheme with which to diagnose salivary gland lesions by FNA and stratify them into broad risk-based diagnostic categories for effective clinical and surgical management. The goal of the Milan group is to put forth a classification scheme that can be used uniformly and consists of standardized and easy-to-apply criteria for diagnosing salivary gland FNA specimens.
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